Evamist.com — Evamist® dosing (estradiol transdermal spray)

The Evamist^® applicator is designed with your patients in mind

Evamist is dosed once daily with 1, 2, or 3 sprays applied to a small area on the inner forearm. Each applicator accurately delivers 75 sprays, giving your patients the right amount of medicine they need each time they use the applicator.¹

Flexible titration with 3 dosing options in 1 applicator

You can adjust the patient’s dose with 1, 2, or 3 sprays of Evamist,
as needed¹:

Dosing adjustments are made by increasing (or decreasing) the number of sprays per day
No need to issue a new prescription to patients initially for dosing adjustments

Metered-dose technology for accurate delivery

The metered-dose transdermal spray (MDTS) applicator delivers consistent and accurate amounts of estradiol¹
Each metered dose ensures that patients apply 1.53 mg of estradiol per spray, delivering 0.021 mg of estradiol to the bloodstream with 1 spray^1,2
Estradiol is absorbed into the stratum corneum, forming a long-lasting depot²
Estradiol is released into the bloodstream on a sustained basis, providing a practical and convenient once-daily dosing regimen^1,2

Flexibility to customize progestogen therapy

May be used in women with or without a uterus
Flexibility to choose progestogen therapy based on your professional judgment
In the Evamist pivotal trial of 454 women, 39% of subjects had an intact uterus²

At the end of the 12-week treatment period with Evamist, these subjects received a daily dose of MPA for 2 weeks³
Only 1 patient treated with Evamist reported vaginal spotting following MPA administration²

^*	Before using the applicator for the first time, it must be primed 3 times with the cover on by pressing down the applicator button with your thumb or index finger.

» References

Important Safety Information

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER, PROBABLE DEMENTIA and UNINTENTIONAL SECONDARY EXPOSURE TO ESTROGEN

See full prescribing information for complete boxed warning

Estrogen-Alone Therapy

•	There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens
•	Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia
•	The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT)
•	The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older

Estrogen Plus Progestin Therapy

•	Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia
•	The WHI estrogen plus progestin substudy reported increased risks of stroke, DVT, pulmonary embolism, and myocardial infarction
•	The WHI estrogen plus progestin study reported increased risks of invasive breast cancer
•	The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older

Estrogens with or without progestins should be prescribed at the lowest effective doses for the shortest duration consistent with the treatment goals for the individual woman.

Unintentional Secondary Exposure

Breast budding and breast masses in prepubertal females and gynecomastia and breast masses in prepubertal males have been reported following unintentional secondary exposure to Evamist by women using this product. In most cases, the condition resolved with removal of Evamist exposure. Women should ensure that children do not come into contact with the site(s) where Evamist is applied. Healthcare providers should advise patients to strictly adhere to recommended instructions for use.

Evamist is an estrogen indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

Evamist should not be used in women with undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active deep vein thrombosis, pulmonary embolism, or history of these conditions; active or recent arterial thromboembolic disease; liver dysfunction or disease; or known or suspected pregnancy.

In a clinical trial with Evamist the most common side effects were headache, breast tenderness, nipple pain, nausea, back pain and nasopharyngitis

Please see full prescribing information for Evamist, including boxed warnings.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.